UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/753,350	12/29/2000	Stephen M. Coutts	252312005706	1391

25226 7590 09/26/2003

MORRISON & FOERSTER LLP
755 PAGE MILL RD
PALO ALTO, CA 94304-1018

EXAMINER	
HUYNH, PHUONG N	
ART UNIT	PAPER NUMBER
1644	

DATE MAILED: 09/26/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/753,350	COUTTS ET AL.	
	Examiner	Art Unit	
	Phuong Huynh	1644	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE *One* MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *29 December 2000* .

2a)☐ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *1 and 22-51* is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☐ Claim(s) _____ is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☒ Claim(s) *1, and 22-51* are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11)☐ The proposed drawing correction filed on _____ is: a)☐ approved b)☐ disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12)☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____ .

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) ☐ The translation of the foreign language provisional application has been received.

15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ .
4) ☐ Interview Summary (PTO-413) Paper No(s). _____ .
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other: .

DETAILED ACTION

I. The location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Art Unit 1644, Group 1640, Technology Center 1600.

II. Claims 1, and 22-51 are pending.

Election/Restrictions

III. Restriction to one of the following inventions is required under 35 U.S.C. 121:

1. Claim 1, drawn to a specific conjugate comprising a biological molecule reacted with a chemically-defined **non-polymeric valency platform molecule of formula 1** and wherein the biological molecule comprises **polynucleotide duplexes** of at least about 20 base pairs, classified in Class 514, subclass 44, Class 514, subclass 114.

2. Claim 1, drawn to a specific conjugate comprising a biological molecule reacted with a chemically-defined **non-polymeric valency platform molecule of formula 2** and wherein the biological molecule comprises **polynucleotide duplexes** of at least about 20 base pairs, classified in Class 424, subclass 193.1, Class 514, subclass 44, Class 514, subclass 114.

3. Claims 22-27, 29-38, 44, and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific carbohydrate**, wherein the **external immunogen** is **a specific drug**, classified in Class 424, subclass 193.1.

4. Claims 22-27, 29-38, 44, and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule,

wherein the **analog molecules** is a **specific lipid**, wherein the external immunogen is a specific **drug**, classified in Class 424, subclass 193.1.

5. Claims 22-27, 29-38, 44, and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule is** a **specific lipopolysaccharide**, wherein the **external immunogen is a specific drug**, classified in Class 424, subclass 193.1.

6. Claims 22-38, 42-43, and 46, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific polypeptide or protein**, wherein the **external immunogen is a specific drug**, classified in Class 424, subclass 193.1.

7. Claims 22-38, 42-43, and 46, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific peptide**, wherein the **external immunogen is a specific drug**, classified in Class 424, subclass 193.1.

8. Claims 22-27, 29-38, 44, and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific glycoprotein**, wherein the **external immunogen is a specific drug**, classified in Class 424, subclass 193.1.

9. Claims 22-27, 29-38, 44, and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific lipoprotein**, wherein the external **immunogen is a specific drug**, classified in Class 424, subclass 193.1.

10. Claims 22-27, 29-38, 44, and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific carbohydrate**, wherein the **external immunogen** is **a specific drug**, classified in Class 424, subclass 193.1.

11. Claims 22-27, 29-38, 44, and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecules** is a **specific lipid**, wherein the **external immunogen is a** specific **allergen**, classified in Class 424, subclass 193.1.

12. Claims 22-27, 29-38, 44, and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule is** a **specific lipopolysaccharide**, wherein the **external immunogen is a specific allergen**, classified in Class 424, subclass 193.1.

13. Claims 22-38, 42-43, and 46, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific polypeptide or protein**, wherein the **external immunogen is a specific allergen**, classified in Class 424, subclass 193.1.

14. Claims 22-38, 42-43, and 46, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific peptide**, wherein the **external immunogen is a specific allergen**, classified in Class 424, subclass 193.1.

15. Claims 22-27, 29-38, 44, and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the

immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific glycoprotein**, wherein the **external immunogen is a specific allergen**, classified in Class 424, subclass 193.1.

16. Claims 22-27, 29-38, 44, and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific lipoprotein**, wherein the external **immunogen is a specific allergen**, classified in Class 424, subclass 193.1.

17. Claims 22-27, 29-38, 44, and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific carbohydrate**, wherein the **external immunogen** is **a specific D immunogen associated with Rh hemolytic disease**, classified in Class 424, subclass 193.1.

18. Claims 22-27, 29-38, 44, and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecules** is a **specific lipid**, wherein the external immunogen is **a specific D immunogen associated with Rh hemolytic disease**, classified in Class 424, subclass 193.1.

19. Claims 22-27, 29-38, 44, and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule is** a **specific lipopolysaccharide**, wherein the **external immunogen** is **a specific D immunogen associated with Rh hemolytic disease**, classified in Class 424, subclass 193.1.

20. Claims 22-38, 42-43, and 46, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific polypeptide or protein**, wherein the **external immunogen** is **a specific D immunogen associated with Rh hemolytic disease**, classified in Class 424, subclass 193.1.

21. Claims 22-38, 42-43, and 46, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific peptide**, wherein the **external immunogen is a specific drug**, classified in Class 424, subclass 193.1.

22. Claims 22-27, 29-38, 44, and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific glycoprotein**, wherein the **external immunogen** is **a specific D immunogen associated with Rh hemolytic disease**, classified in Class 424, subclass 193.1.

23. Claims 22-27, 29-38, 44, and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific lipoprotein**, wherein the external **immunogen** is **a specific D immunogen associated with Rh hemolytic disease**, classified in Class 424, subclass 193.1.

24. Claims 22-27, 29-36, 39-41, 44 and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific carbohydrate**, wherein the **immunogen** is **a specific self immunogen**, classified in Class 424, subclass 193.1.

25. Claims 22-27, 29-36, 39-41, 44 and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific lipid**, wherein the **immunogen** is **a specific self immunogen**, classified in Class 424, subclass 193.1.

26. Claims 22-27, 29-36, 39-41, 44 and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific lipopolysaccharide**, wherein the **immunogen** is **a specific self immunogen**, classified in Class 424, subclass 193.1.

27. Claims 22-36, 39-43 and 46, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific polypeptide or protein**, wherein the **immunogen** is **a specific self immunogen**, classified in Class 424, subclass 193.1.

28. Claims 22-36, 39-43 and 46, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific peptide**, wherein the **immunogen** is **a specific self immunogen**, classified in Class 424, subclass 193.1.

29. Claims 22-27, 29-36, 39-41, 44 and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific glycoprotein**, wherein the **immunogen** is **a specific self immunogen**, classified in Class 424, subclass 193.1.

30. Claims 22-27, 29-36, 39-41, 44 and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific lipoprotein**, wherein the **immunogen** is **a specific self immunogen**, classified in Class 424, subclass 193.1.

31. Claims 22-27, 29-36, 45 and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific carbohydrate**, wherein the **immunogen** is **unidentified immunogen**, classified in Class 424, subclass 193.1.

32. Claims 22-27, 29-36, 45 and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific lipid**, wherein the **immunogen** is **unidentified immunogen**, classified in Class 424, subclass 193.1.

33. Claims 22-27, 29-36, 45 and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific lipopolysaccharide**, wherein the **immunogen** is **unidentified immunogen**, classified in Class 424, subclass 193.1.

34. Claims 22-36 and 45-46, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific polypeptide or protein**, wherein the **immunogen** is **unidentified immunogen**, classified in Class 424, subclass 193.1.

35. Claims 22-36 and 45-46, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen

conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific peptide**, wherein the **immunogen** is **unidentified immunogen**, classified in Class 424, subclass 193.1.

36. Claims 22-27, 29-36, 45 and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific glycoprotein**, wherein the **immunogen** is **unidentified immunogen**, classified in Class 424, subclass 193.1.

37. Claims 22-27, 29-36, 45 and 47, drawn to a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific lipoprotein**, wherein the **immunogen** is **unidentified immunogen**, classified in Class 424, subclass 193.1.

38. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific carbohydrate**, wherein the **external immunogen** is **a specific drug**, classified in Class 424, subclass 193.1.

39. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecules** is a **specific lipid**, wherein the external immunogen is a specific **drug**, classified in Class 424, subclass 193.1.

40. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule is** a **specific lipopolysaccharide**, wherein the **external immunogen is a specific drug**, classified in Class 424, subclass 193.1.

41. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific polypeptide or protein**, wherein the **external immunogen is a specific drug**, classified in Class 424, subclass 193.1.

42. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific peptide**, wherein the **external immunogen is a specific drug**, classified in Class 424, subclass 193.1.

43. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific glycoprotein**, wherein the **external immunogen is a specific drug**, classified in Class 424, subclass 193.1.

44. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific lipoprotein**, wherein the external **immunogen is a specific drug**, classified in Class 424, subclass 193.1.

45. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific carbohydrate**, wherein the **external immunogen** is **a specific drug**, classified in Class 424, subclass 193.1.

46. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecules** is a **specific lipid**, wherein the **external immunogen is a** specific **allergen**, classified in Class 424, subclass 193.1.

47. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule is** a **specific lipopolysaccharide**, wherein the **external immunogen is a specific allergen**, classified in Class 424, subclass 193.1.

48. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific polypeptide or protein**, wherein the **external immunogen is a specific allergen**, classified in Class 424, subclass 193.1.

49. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific peptide**, wherein the **external immunogen is a specific allergen**, classified in Class 424, subclass 193.1.

50. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific glycoprotein**, wherein the **external immunogen is a specific allergen**, classified in Class 424, subclass 193.1.

51. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific lipoprotein**, wherein the external **immunogen is a specific allergen**, classified in Class 424, subclass 193.1.

52. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific carbohydrate**, wherein the **external immunogen** is **a specific D immunogen associated with Rh hemolytic disease**, classified in Class 424, subclass 193.1.

53. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecules** is a **specific lipid**, wherein the external immunogen is **a specific D immunogen associated with Rh hemolytic disease**, classified in Class 424, subclass 193.1.

54. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule is** a **specific lipopolysaccharide**, wherein the **external immunogen** is **a specific D immunogen associated with Rh hemolytic disease**, classified in Class 424, subclass 193.1.

55. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific polypeptide or protein**, wherein the **external immunogen** is **a specific D immunogen associated with Rh hemolytic disease**, classified in Class 424, subclass 193.1.

57. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific peptide**, wherein the **external immunogen is a specific drug**, classified in Class 424, subclass 193.1.

58. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific glycoprotein**, wherein the **external immunogen** is **a specific D immunogen associated with Rh hemolytic disease**, classified in Class 424, subclass 193.1.

59. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific lipoprotein**, wherein the external **immunogen** is **a specific D immunogen associated with Rh hemolytic disease**, classified in Class 424, subclass 193.1.

60. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific carbohydrate**, wherein the **immunogen** is **a specific self immunogen**, classified in Class 424, subclass 193.1.

61. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific lipid**, wherein the **immunogen** is **a specific self immunogen**, classified in Class 424, subclass 193.1.

62. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific lipopolysaccharide**, wherein the **immunogen** is **a specific self immunogen**, classified in Class 424, subclass 193.1.

63. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific polypeptide or protein**, wherein the **immunogen** is **a specific self immunogen**, classified in Class 424, subclass 193.1.

64. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific peptide**, wherein the **immunogen** is **a specific self immunogen**, classified in Class 424, subclass 193.1.

65. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific glycoprotein**, wherein the **immunogen** is **a specific self immunogen**, classified in Class 424, subclass 193.1.

66. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific lipoprotein**, wherein the **immunogen** is **a specific self immunogen**, classified in Class 424, subclass 193.1.

67. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific carbohydrate**, wherein the **immunogen** is **unidentified immunogen**, classified in Class 424, subclass 193.1.

68. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific lipid**, wherein the **immunogen** is **unidentified immunogen**, classified in Class 424, subclass 193.1.

69. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific lipopolysaccharide**, wherein the **immunogen** is **unidentified immunogen**, classified in Class 424, subclass 193.1.

70. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific polypeptide or protein**, wherein the **immunogen** is **unidentified immunogen**, classified in Class 424, subclass 193.1.

71. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific peptide**, wherein the **immunogen** is **unidentified immunogen**, classified in Class 424, subclass 193.1.

72. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific glycoprotein**, wherein the **immunogen** is **unidentified immunogen**, classified in Class 424, subclass 193.1.

73. Claims 48-49, drawn to a method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific lipoprotein**, wherein the **immunogen** is **unidentified immunogen**, classified in Class 424, subclass 193.1.

74. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific carbohydrate**, wherein the **external immunogen** is **a specific drug**, classified in Class 435, subclass 69.1.

75. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecules** is a **specific lipid**, wherein the external immunogen is a specific **drug**, classified in Class 435, subclass 69.1.

76. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule is** a **specific lipopolysaccharide**, wherein the **external immunogen is a specific drug**, classified in Class 435, subclass 69.1.

77. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific polypeptide or protein**, wherein the **external immunogen is a specific drug**, classified in Class 435, subclass 69.1.

78. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific peptide**, wherein the **external immunogen is a specific drug**, classified in Class 435, subclass 69.1.

79. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific glycoprotein**, wherein the **external immunogen is a specific drug**, classified in Class 435, subclass 69.1.

80. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific lipoprotein**, wherein the external **immunogen is a specific drug**, classified in Class 435, subclass 69.1.

81. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific carbohydrate**, wherein the **external immunogen** is **a specific drug**, classified in Class 435, subclass 69.1.

82. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecules** is a **specific lipid**, wherein the **external immunogen is a** specific **allergen**, classified in Class 435, subclass 69.1.

83. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the

immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule is** a **specific lipopolysaccharide**, wherein the **external immunogen is a specific allergen**, classified in Class 435, subclass 69.1.

84. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific polypeptide or protein**, wherein the **external immunogen is a specific allergen,** classified in Class 435, subclass 69.1.

85. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific peptide**, wherein the **external immunogen is a specific allergen**, classified in Class 435, subclass 69.1.

86. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific glycoprotein**, wherein the **external immunogen is a specific allergen**, classified in Class 435, subclass 69.1.

87. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific lipoprotein**, wherein the external **immunogen is a specific allergen,** classified in Class 435, subclass 69.1.

88. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific carbohydrate**, wherein the **external**

immunogen is **a specific D immunogen associated with Rh hemolytic disease**, classified in Class 435, subclass 69.1.

89. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecules** is a **specific lipid**, wherein the external immunogen is **a specific D immunogen associated with Rh hemolytic disease**, classified in Class 435, subclass 69.1.

90. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule is** a **specific lipopolysaccharide**, wherein the **external immunogen** is **a specific D immunogen associated with Rh hemolytic disease**, classified in Class 435, subclass 69.1.

91. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific polypeptide or protein**, wherein the **external immunogen** is **a specific D immunogen associated with Rh hemolytic disease**, classified in Class 435, subclass 69.1.

92. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific peptide**, wherein the **external immunogen is a specific drug**, classified in Class 435, subclass 69.1.

93. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the

immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific glycoprotein**, wherein the **external immunogen** is **a specific D immunogen associated with Rh hemolytic disease**, classified in Class 435, subclass 69.1.

94. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is a **specific lipoprotein**, wherein the external **immunogen** is **a specific D immunogen associated with Rh hemolytic disease**, classified in Class 435, subclass 69.1.

95. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific carbohydrate**, wherein the **immunogen** is **a specific self immunogen**, classified in Class 435, subclass 69.1.

96. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific lipid**, wherein the **immunogen** is **a specific self immunogen**, classified in Class 435, subclass 69.1.

97. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific lipopolysaccharide**, wherein the **immunogen** is **a specific self immunogen**, classified in Class 435, subclass 69.1.

98. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the

immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific polypeptide or protein**, wherein the **immunogen** is **a specific self immunogen**, classified in Class 435, subclass 69.1.

99. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific peptide**, wherein the **immunogen** is **a specific self immunogen**, classified in Class 435, subclass 69.1.

100. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific glycoprotein**, wherein the **immunogen** is **a specific self immunogen**, classified in Class 435, subclass 69.1.

101. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific lipoprotein**, wherein the **immunogen** is **a specific self immunogen**, classified in Class 435, subclass 69.1.

102. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific carbohydrate**, wherein the **immunogen** is **unidentified immunogen**, classified in Class 435, subclass 69.1.

103. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule,

wherein the **analog molecule** is **a specific lipid**, wherein the **immunogen** is **unidentified immunogen**, classified in Class 435, subclass 69.1.

104. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific lipopolysaccharide**, wherein the **immunogen** is **unidentified immunogen**, classified in Class 435, subclass 69.1.

105. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific polypeptide or protein**, wherein the **immunogen** is **unidentified immunogen**, classified in Class 435, subclass 69.1.

106. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific peptide**, wherein the **immunogen** is **unidentified immunogen**, classified in Class 435, subclass 69.1.

107. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific glycoprotein**, wherein the **immunogen** is **unidentified immunogen**, classified in Class 435, subclass 69.1.

108. Claims 50-51, drawn to a method of making a composition comprising a plurality of a conjugate wherein said conjugate comprises at least two analog molecules of the immunogen conjugated to a specific chemically defined valency platform molecule, wherein the **analog molecule** is **a specific lipoprotein**, wherein the **immunogen** is **unidentified immunogen**, classified in Class 435, subclass 69.1.

The inventions are distinct, each from the other because of the following reasons:

Inventions of Groups 1-37 are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the products as claimed differ with respect to their structure and physiochemical properties. Further, a prior art search also requires a literature search. It is a burden for the examiner to search more than one invention. Therefore, they are patentably distinct.

Inventions of Groups 38-108 are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the methods of treating with different products versus the method of making the specific product differ with their respect to their process steps and endpoints. Therefore, they are patentably distinct.

Inventions of Groups 1-37 and Groups 38-108 are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the products as claimed can be used in materially different process such as screening assays. Therefore, they are patentably distinct.

IV. Irrespective of whichever group the applicant may elect, the applicant is further required under 35 U.S.C. 121 to elect:

If Group 1 or 2 is elected, the Applicant is required to elect a specific conjugate comprising (1) a specific chemical or a specific biological molecule and (2) a specific moieties such as the ones recited in claim 1.

If any one of Groups 3-37 is elected, the Applicant is required to elect a specific composition comprising the (1) specific analog such as the specific carbohydrate, lipid, lipopolysaccharide, polypeptide, peptide, glycoprotein, or lipoprotein, (2) the specific immunogen such as the ones associated with the specific disease as recited in claim 41, (3) whether the immunogen and the analog molecules are same or different class. These compositions comprising the different analog of different immunogen are patentably distinct because they differ with respect to their structures, physiochemical properties and mode of action. Therefore, they are patentably distinct.

If any one of Groups 38-108 is elected, the Applicant is required to elect a specific method comprising the specific composition wherein the composition comprising the (1) specific analog such as the specific carbohydrate, lipid, lipopolysaccharide, polypeptide, peptide, glycoprotein, or lipoprotein, (2) the specific immunogen such as the ones associated with the specific disease as recited in claim 41, (3) whether the immunogen and the analog molecules are same or different class. The methods of treating and making the specific composition comprising the specific analog of the specific immunogen not only differ with respect to the process steps and endpoint but also differ with respect to their structures, and physiochemical properties in the composition. Therefore, they are patentably distinct.

V. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1, 22, 48 and 50 are generic.

VI. Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

VII. Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. M.P.E.P. § 809.02(a).

VIII. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. § 103 of the other invention.

IX. Due to the complexity of the claimed invention an oral restriction was not made.

X. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.

XI. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

XII. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phuong Huynh "NEON" whose telephone number is (703) 308-4844. The examiner can normally be reached Monday through Friday from 9:00 am to 5:30 p.m. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

XIII. Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform to the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.

Phuong N. Huynh, Ph.D.
Patent Examiner
Technology Center 1600
Sept 22, 2003

CHRISTINA CHAN
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600